BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakajima T, Moriguchi M, Mitsumoto Y, Katagishi T, Kimura H, Shintani H, Deguchi T, Okanoue T, Kagawa K, Ashihara T. Simple tumor profile chart based on cell kinetic parameters and histologic grade is useful for estimating the natural growth rate of hepatocellular carcinoma. Hum Pathol. 2002;33:92-99. [PMID: 11823978 DOI: 10.1053/hupa.2002.30194] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Nakajima T, Moriguchi M, Mitsumoto Y, Sekoguchi S, Nishikawa T, Takashima H, Watanabe T, Katagishi T, Kimura H, Okanoue T, Kagawa K. Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma. Mod Pathol 2004;17:722-7. [DOI: 10.1038/modpathol.3800115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
2 Quaglia A, McStay M, Stoeber K, Loddo M, Caplin M, Fanshawe T, Williams G, Dhillon A. Novel markers of cell kinetics to evaluate progression from cirrhosis to hepatocellular carcinoma. Liver Int 2006;26:424-32. [PMID: 16629645 DOI: 10.1111/j.1478-3231.2006.01242.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
3 Kim SS, Kang TW, Song KD, Cho SK, Lee MW, Rhim H, Sinn DH, Jung SH. Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. Clin Radiol 2017;72:141-9. [PMID: 27742104 DOI: 10.1016/j.crad.2016.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
4 Sangro B. Refined tools for the treatment of hepatocellular carcinoma. J Hepatol 2005;42:629-31. [PMID: 15826709 DOI: 10.1016/j.jhep.2005.02.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534-540. [PMID: 15048797 DOI: 10.1002/lt.20128] [Cited by in Crossref: 298] [Cited by in F6Publishing: 263] [Article Influence: 16.6] [Reference Citation Analysis]
6 Wigg AJ, Palumbo K, Wigg DR. Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use. J Gastroenterol Hepatol. 2010;25:664-671. [PMID: 20074152 DOI: 10.1111/j.1440-1746.2009.06126.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
7 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
8 Tezuka M, Hayashi K, Kubota K, Sekine S, Okada Y, Ina H, Irie T. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig Dis Sci. 2007;52:783-788. [PMID: 17268830 DOI: 10.1007/s10620-006-9537-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
9 Nakajima T, Moriguchi M, Watanabe T, Noda M, Fuji N, Minami M, Itoh Y, Okanoue T. Recurrence of hepatocellular carcinoma with rapid growth after spontaneous regression. World J Gastroenterol 2004; 10(22): 3385-3387 [PMID: 15484326 DOI: 10.3748/wjg.v10.i22.3385] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
10 Qian HL, Peng XX, Chen SH, Ye HM, Qiu JH. p62 expression in primary carcinomas of the digestive system. World J Gastroenterol 2005; 11(12): 1788-1792 [PMID: 15793865 DOI: 10.3748/wjg.v11.i12.1788] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
11 Mehrara E, Forssell-Aronsson E. Analysis of inter-patient variations in tumour growth rate. Theor Biol Med Model 2014;11:21. [PMID: 24885724 DOI: 10.1186/1742-4682-11-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, Do RKG, Ehman EC, Fowler KJ, Hussain HK, Jha RC, Karam AR, Mamidipalli A, Marks RM, Mitchell DG, Morgan TA, Ohliger MA, Shah A, Vu KN, Sirlin CB; LI-RADS Evidence Working Group. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology 2018;286:29-48. [PMID: 29166245 DOI: 10.1148/radiol.2017170554] [Cited by in Crossref: 131] [Cited by in F6Publishing: 128] [Article Influence: 26.2] [Reference Citation Analysis]
13 Wrzesinski K, Fey SJ. Metabolic Reprogramming and the Recovery of Physiological Functionality in 3D Cultures in Micro-Bioreactors. Bioengineering (Basel) 2018;5:E22. [PMID: 29518979 DOI: 10.3390/bioengineering5010022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
14 Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release. 2012;164:265-275. [PMID: 22800576 DOI: 10.1016/j.jconrel.2012.07.013] [Cited by in Crossref: 204] [Cited by in F6Publishing: 201] [Article Influence: 20.4] [Reference Citation Analysis]
15 Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B, Marrero J, Parikh N, Singal AG. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut 2021;70:401-7. [PMID: 32398224 DOI: 10.1136/gutjnl-2020-321040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
16 Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, Ravaioli M, La Barba G, Cavallari A, Bolondi L, Pinna AD. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005;43:310-6. [PMID: 15970351 DOI: 10.1016/j.jhep.2005.03.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
17 Chernyak V, Kobi M, Flusberg M, Fruitman KC, Sirlin CB. Effect of threshold growth as a major feature on LI-RADS categorization. Abdom Radiol 2017;42:2089-100. [DOI: 10.1007/s00261-017-1105-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Tang A, Valasek MA, Sirlin CB. Update on the Liver Imaging Reporting and Data System: What the Pathologist Needs to Know. Adv Anat Pathol. 2015;22:314-322. [PMID: 26262514 DOI: 10.1097/pap.0000000000000089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
19 Talkington A, Durrett R. Estimating Tumor Growth Rates In Vivo. Bull Math Biol. 2015;77:1934-1954. [PMID: 26481497 DOI: 10.1007/s11538-015-0110-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]